# The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome

> **NCT03141554** · PHASE4 · COMPLETED · sponsor: **Mundipharma Manufacturing Pte Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Oral Health

## Interventions

- **DRUG:** 1% Betadine® PVP-I based mouth wash and gargle,
- **DRUG:** 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
- **DRUG:** Normal saline gargle

## Key facts

- **NCT ID:** NCT03141554
- **Lead sponsor:** Mundipharma Manufacturing Pte Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-05
- **Primary completion:** 2017-05-19
- **Final completion:** 2017-05-19
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03141554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03141554, "The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03141554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*